NASDAQ$VRCA
Verrica Pharmaceuticals Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Verrica reported a net loss for Q2 2020, with key leadership additions and progress on VP-102 regulatory resubmission.
Verrica Pharmaceuticals reported a net loss of $9.4 million for the second quarter of 2020. The company is focusing on resubmitting the New Drug Application for VP-102 and strengthened its leadership team. They also entered into an option agreement with Torii Pharmaceutical for VP-102 in Japan.
- Verrica received a Complete Response Letter from the FDA for VP-102 NDA and plans to request a Type A meeting with the FDA in Q3 2020.
- Key personnel changes were made to strengthen expertise in clinical, CMC, and regulatory affairs.
- An option agreement was signed with Torii Pharmaceutical for the development and commercialization of VP-102 in Japan.
- Two new pooled analyses of the Phase 3 CAMP trials of VP-102 in molluscum were presented at the virtual American Academy of Dermatology 2020 Annual Meeting.
Headline financials
Revenue & EPS history
Verrica · Revenue · Quarterly
$5.02M
Forward guidance
Verrica is focused on resubmitting the NDA for VP-102 and advancing its pipeline.
Tailwinds
- Company expects to discuss with the FDA regarding the issues raised in the CRL and the Company’s plans to address them
- Potential approval of the NDA for VP-102 following resubmission
- Potential benefits and potential approval and commercialization of VP-102 for the treatment of molluscum
- Company's plans with respect to planned clinical trials of VP-102 for common warts and VP-103 for plantar warts
- Torii’s potential exercise of their option under the Option Agreement and the potential terms and payments under the proposed license agreement.
Headwinds
- Uncertainties inherent in the drug development process
- Uncertainties inherent in the regulatory approval process
- Verrica’s reliance on third parties over which it may not always have full control
- Uncertainties related to the COVID-19 pandemic
- Other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+18.6%
Q1 2024
Best reaction
-47.9%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -15.3% | — | |
| Q4 2025 | +4.7% | +3.2% | -14.5% | |
| Q3 2025 | +3.2% | +15.8% | +104.7% | |
| Q1 2025 | +2.9% | -0.8% | -3.0% | |
| Q4 2024 | -7.6% | +0.5% | -25.3% | |
| Q3 2024 | -47.9% | -45.8% | -22.2% | |
| Q2 2024 | -44.8% | -43.8% | -62.6% | |
| Q1 2024 | +18.6% | +8.4% | +7.3% | |
| Q4 2023 | -3.0% | -10.1% | +3.5% | |
| Q3 2023 | -13.6% | -17.7% | +7.6% | |
| Q2 2023 | +7.6% | +1.6% | -18.5% | |
| Q1 2023 | -1.4% | -7.1% | -13.9% | |
| Q4 2022 | -6.9% | +1.5% | -21.6% | |
| Q3 2022 | -3.1% | +3.1% | +43.7% | |
| Q2 2022 | +17.1% | +9.6% | +18.8% | |
| Q1 2022 | -1.6% | -7.8% | -63.0% | |
| Q4 2021 | +1.3% | -7.7% | +1.9% | |
| Q3 2021 | -4.2% | -5.9% | -22.2% | |
| Q2 2021 | -1.6% | -0.7% | +12.6% | |
| Q1 2021 | -0.8% | -0.2% | -14.8% | |
| Q4 2020 | -9.6% | -0.2% | +1.3% | |
| Q3 2020 | +13.9% | +13.1% | +32.3% | |
| Q2 2020 | +5.6% | +4.8% | +29.6% | |
| Q1 2020 | +10.5% | +2.8% | +24.0% | |
| Q4 2019 | -12.1% | -7.5% | +31.3% | |
| Q3 2019 | +0.8% | +4.0% | -7.3% | |
| Q2 2019 | +2.6% | -9.3% | -2.3% | |
| Q1 2019 | +1.0% | -3.3% | -23.4% | |
| Q4 2018 | -7.5% | +1.1% | -8.0% | |
| Q3 2018 | -3.8% | +5.6% | -22.7% | |
| Q2 2018 | -0.9% | +2.7% | +13.8% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro